赛克赛斯科创板IPO获受理专注于体内可吸收植介入医疗器械赛道

智通财经网03-24

智通财经APP获悉，3月24日，赛克赛斯生物科技股份有限公司(简称：赛克赛斯)上交所科创板IPO已受理。光大证券为其保荐机构，拟募资6.35亿元。招股书显示，赛克赛斯专注于体内可吸收植介入医疗器械的研发、生产和销售。公司主要产品为可吸收硬脑膜封合医用胶、可吸收血管封合医用胶、复合微孔多聚糖止血粉和手术防粘连液。公司的可吸收硬脑膜封合医用胶是国内细分领域首款成功研发的创新产品。目前，其在国内硬脑膜...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2621066933?lang=zh_CN&edition=full","thumbnail":"https://img.zhitongcaijing.com/image/20260324/20260324184134_36345.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","is_english":false,"pubTime":"2026-03-24 18:48","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2621066933","market":"us","top_or_hot":-1,"title":"赛克赛斯科创板IPO获受理 专注于体内可吸收植介入医疗器械赛道","media":"智通财经网","content":"<div>\n<p>智通财经APP获悉，3月24日，赛克赛斯生物科技股份有限公司(简称：赛克赛斯)上交所科创板IPO已受理。光大证券为其保荐机构，拟募资6.35亿元。招股书显示，赛克赛斯专注于体内可吸收植介入医疗器械的研发、生产和销售。公司主要产品为可吸收硬脑膜封合医用胶、可吸收血管封合医用胶、复合微孔多聚糖止血粉和手术防粘连液。公司的可吸收硬脑膜封合医用胶是国内细分领域首款成功研发的创新产品。目前，其在国内硬脑膜...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1418127.html\">网页链接</a>\n\n</div>\n","source":"highlight_zhitongcaijin","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>赛克赛斯科创板IPO获受理 专注于体内可吸收植介入医疗器械赛道</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n赛克赛斯科创板IPO获受理 专注于体内可吸收植介入医疗器械赛道\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-24 18:48 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1418127.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，3月24日，赛克赛斯生物科技股份有限公司(简称：赛克赛斯)上交所科创板IPO已受理。光大证券为其保荐机构，拟募资6.35亿元。招股书显示，赛克赛斯专注于体内可吸收植介入医疗器械的研发、生产和销售。公司主要产品为可吸收硬脑膜封合医用胶、可吸收血管封合医用胶、复合微孔多聚糖止血粉和手术防粘连液。公司的可吸收硬脑膜封合医用胶是国内细分领域首款成功研发的创新产品。目前，其在国内硬脑膜...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1418127.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1222","symbol_name":"医疗保健用品","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1418127.html","article_id":"2621066933","we_media_id":null,"thumbnails":["https://img.zhitongcaijing.com/image/20260324/20260324184134_36345.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621066933","pubTimestamp":1774349332,"columns":[],"sourceInfo":{"source_id":"highlight_zhitongcaijin","name":"智通财经网"},"weMediaInfo":null,"summary":"3月24日，赛克赛斯生物科技股份有限公司上交所科创板IPO已受理，拟募资6.35亿元。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159883":"医疗器械","159982":"中证500","BK1222":"医疗保健用品","09996":"沛嘉医疗-B","BK1574":"生物医药B类股","09997":"康基医疗","BK1583":"高瓴概念","BK1100":"医疗保健设备"},"translate_title":"Sykes Science and Technology Innovation Board IPO accepted, focusing on in vivo absorbable implant interventional medical device track","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159883":1.5,"159982":1.5,"09996":1.5,"09997":1.5},"content_text":"智通财经APP获悉，3月24日，赛克赛斯生物科技股份有限公司(简称：赛克赛斯)上交所科创板IPO已受理。光大证券为其保荐机构，拟募资6.35亿元。招股书显示，赛克赛斯专注于体内可吸收植介入医疗器械的研发、生产和销售。公司主要产品为可吸收硬脑膜封合医用胶、可吸收血管封合医用胶、复合微孔多聚糖止血粉和手术防粘连液。公司的可吸收硬脑膜封合医用胶是国内细分领域首款成功研发的创新产品。目前，其在国内硬脑膜封合胶市场占据约91%的市场份额，市占率稳居第一。公司的可吸收血管封合医用胶系该细分领域唯一的国产产品，在国内血管封合胶领域占据约70%的市场份额，成功实现了进口替代，预计该产品有望进一步提升市场渗透率。 与此同时，公司的复合微孔多聚糖止血粉及手术防粘连液也在国内占据重要地位，复合微孔多聚糖止血粉在微粉类可吸收止血材料的国内市场占有率为 27.67%，位居细分行业第一。手术防粘连液在国内手术防粘连材料市场的占有率为  20.53%，市场份额位居行业第二。截至报告期末，公司已拥有25款医疗器械产品，多项重点研发管线均在顺利推进之中，其中3个项目已处于注册审评阶段，3个项目处于临床试验阶段，7个项目处于工艺研究及注册检验阶段。在研产品涵盖神经外科、骨科、肿瘤放射科等全球高景气赛道。本次募集资金扣除发行费用后的净额将用于以下项目：财务方面，于2023年度、2024年度、2025年度，公司实现营业收入分别为3.79亿元、3.31亿元、3.38亿元人民币；同期，净利润分别约为1.53亿元、1.61亿元、1.68亿元人民币。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621066933","isCrawlerRequest":true}

赛克赛斯科创板IPO获受理 专注于体内可吸收植介入医疗器械赛道

精彩评论

赛克赛斯科创板IPO获受理专注于体内可吸收植介入医疗器械赛道